ZDA
LLY icon

Zweig-DiMenna Associates’s Eli Lilly LLY Stock Holding History

Zweig-DiMenna Associates’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,375
Closed -$4.15M – 90
2024
Q4 		$4.15M Sell
5,375
-16,765
-76% -$13.9M 0.31% 70
2024
Q3 		$19.6M Buy
22,140
+2,460
+13% +$2.21M 1.98% 15
2024
Q2 		$17.8M Buy
19,680
+6,125
+45% +$4.9M 2.01% 15
2024
Q1 		$10.5M Buy
+13,555
New +$9.65M 0.92% 40
2016
Q1 		– Sell
-135,000
Closed -$11.4M – 239
2015
Q4 		$11.4M Buy
+135,000
New +$11.2M 0.57% 64
2013
Q4 		– Sell
-5,100
Closed -$257K – 284
2013
Q3 		$257K Buy
+5,100
New +$267K 0.01% 178

Other funds holding LLY

PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Zweig-DiMenna Associates's LLY Position: Q1 2025 in Review

Zweig-DiMenna Associates sold out of Eli Lilly (LLY) in Q1 2025, closing a stake of 5,375 shares — an estimated $4.15M sold.

Zweig-DiMenna Associates first reported a position in LLY in Q3 2013 and held it in 6 quarters. The position peaked at $19.6M in Q3 2024. 3,927 funds tracked by Wall St. Rank hold LLY as of Q1 2025.

  • Zweig-DiMenna Associates reported no remaining Eli Lilly position as of Q1 2025 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 5,375 Eli Lilly shares in Q1 2025, an estimated $4.15M.
  • Zweig-DiMenna Associates first reported a position in Eli Lilly in Q3 2013 and held it in 6 quarters.
  • Zweig-DiMenna Associates's Eli Lilly position peaked at $19.6M in Q3 2024.
  • 3,927 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2025.

Based on Zweig-DiMenna Associates's 13F filing for Q1 2025, filed 7 May 2025.